{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:13:16Z","timestamp":1767373996697,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund und Ziel der Arbeit<\/jats:title>\n                <jats:p>Granuloma anulare (GA) ist eine nichtinfekti\u00f6se, granulomat\u00f6se Erkrankung der Haut, die meist lokalisiert und selbstlimitierend ist. 15\u202f% der F\u00e4lle zeigen eine Disseminierung mit h\u00e4ufig protrahiertem Krankheitsverlauf. Ziel dieser Studie ist, das Patientenkollektiv mit disseminiertem GA an einer deutschen Universit\u00e4tsklinik und die Behandlungsmodalit\u00e4ten zu charakterisieren.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Es erfolgte eine retrospektive monozentrische Auswertung am Universit\u00e4tsklinikum Regensburg im Zeitraum zwischen 2021 und 2023 mit deskriptiv-statistischer Auswertung des Patientenkollektivs und der eingesetzten Therapieverfahren.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Im Zeitraum wurden 239 Patienten mit GA identifiziert, davon zeigten 33\u00a0Patienten ein histologisch gesichertes disseminiertes GA. 25\u00a0Patienten (76\u202f%) waren weiblich, das Durchschnittsalter lag bei 57,4\u202f\u00b1\u200914,4 Jahren. 17\u00a0Patienten (53\u202f%) verneinten Beschwerden, h\u00e4ufige Symptome umfassten Dys\u00e4sthesien, Juckreiz und Schmerzen. H\u00e4ufige Begleiterkrankungen waren Diabetes mellitus, Schilddr\u00fcsenerkrankungen, atopische Dermatitis und koronare Herzerkrankung. Therapeutisch wurden in absteigender H\u00e4ufigkeit topische Glukokortikoide, systemische Glukokortikoide, Phototherapie, topische Calcineurininhibitoren und Dimethylfumarat eingesetzt. Nur 6\u00a0Patienten (18\u202f%) zeigten eine partielle oder vollst\u00e4ndige Remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Aufgrund fehlender zugelassener Therapien werden unzureichend wirksame Therapien bei disseminiertem GA eingesetzt. Prospektive, randomisierte, placebokontrollierte Studien sind erforderlich, um die Wirksamkeit neuartiger zielgerichteter therapeutischer Verfahren zu untersuchen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-024-05436-2","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T15:05:01Z","timestamp":1734534301000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Klinische Variablen und Management des disseminierten Granuloma anulare\u00a0\u2013 eine monozentrische retrospektive Auswertung von 33\u00a0F\u00e4llen aus den Jahren 2021 bis 2023","Clinical variables and management of disseminated granuloma annulare\u00a0\u2014 monocentric retrospective analysis of 33\u00a0cases between 2021 and 2023"],"prefix":"10.1007","volume":"76","author":[{"given":"Michael","family":"Spindler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Berneburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadett","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"K\u00f6gel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Niebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"5","key":"5436_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-4632.2011.04930.x","volume":"52","author":"U Acharya","year":"2013","unstructured":"Acharya\u00a0U (2013) Successful treatment of disseminated granuloma annulare with oral fumaric acid esters. Int J Dermatol 52(5):633\u2013634","journal-title":"Int J Dermatol"},{"key":"5436_CR2","unstructured":"Aksu AEK, Erdil D\u0130, Ba\u015f VM et\u00a0al (2023) Clinical and Histopathological Evaluation of Forty-one Cases of Pediatric Granuloma Annulare. Dermatol Pract Concept 13(1)"},{"issue":"1","key":"5436_CR3","first-page":"e21242","volume":"14","author":"MA Al Ameer","year":"2022","unstructured":"Al Ameer\u00a0MA, Al-Natour\u00a0SH, Alsahaf\u00a0HAA et\u00a0al (2022) Eruptive Granuloma Annulare in an Elderly Man With Diabetes. Cureus 14(1):e21242","journal-title":"Cureus"},{"issue":"7","key":"5436_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamadermatol.2021.1805","volume":"157","author":"JS Barbieri","year":"2021","unstructured":"Barbieri\u00a0JS, Rosenbach\u00a0M, Rodriguez\u00a0O et\u00a0al (2021) Association of Granuloma Annulare With Type\u00a02 Diabetes, Hyperlipidemia, Autoimmune Disorders, and Hematologic Malignant Neoplasms. JAMA Dermatol 157(7):817\u2013823","journal-title":"JAMA Dermatol"},{"issue":"3","key":"5436_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ajd.13875","volume":"63","author":"X Bosch-Amate","year":"2022","unstructured":"Bosch-Amate\u00a0X, Serra-Garc\u00eda\u00a0L, Alamon-Reig\u00a0F et\u00a0al (2022) Treatment of granuloma annulare with tofacitinib. Australas J Dermatol 63(3):400\u2013403","journal-title":"Australas J Dermatol"},{"issue":"2","key":"5436_CR6","doi-asserted-by":"publisher","first-page":"e15250","DOI":"10.1111\/dth.15250","volume":"35","author":"E Cammarata","year":"2022","unstructured":"Cammarata\u00a0E, Lappi\u00a0A, Nicola\u00a0S et\u00a0al (2022) Generalized granuloma annulare: Narrow-band UVB phototherapy combined with tacrolimus ointment. Dermatol Ther 35(2):e15250","journal-title":"Dermatol Ther"},{"issue":"5","key":"5436_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/ijd.14350","volume":"58","author":"A Chen","year":"2019","unstructured":"Chen\u00a0A, Truong\u00a0AK, Worswick\u00a0S (2019) The role of biologics in the treatment of chronic granuloma annulare. Int J Dermatol 58(5):622\u2013626","journal-title":"Int J Dermatol"},{"issue":"1","key":"5436_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0190-9622(89)70005-0","volume":"20","author":"K Dabski","year":"1989","unstructured":"Dabski\u00a0K, Winkelmann\u00a0RK (1989) Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J\u00a0Am Acad Dermatol 20(1):39\u201347","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5436_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jdcr.2019.10.016","volume":"6","author":"W Damsky","year":"2020","unstructured":"Damsky\u00a0W, King\u00a0BA (2020) Treatment of granuloma annulare with tofacitinib 2\u202f% ointment. JAAD Case Rep 6(1):69\u201371","journal-title":"JAAD Case Rep"},{"issue":"3","key":"5436_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000083514","volume":"210","author":"B Eberlein-K\u00f6nig","year":"2005","unstructured":"Eberlein-K\u00f6nig\u00a0B, Mempel\u00a0M, Stahlecker\u00a0J et\u00a0al (2005) Disseminated granuloma annulare\u2014treatment with fumaric acid esters. Dermatology 210(3):223\u2013226","journal-title":"Dermatology"},{"issue":"10","key":"5436_CR11","first-page":"1026","volume":"13","author":"P Elsner","year":"2015","unstructured":"Elsner\u00a0P, Schliemann\u00a0S (2015) Does disseminated granuloma annulare require treatment? Thoughts on the definition of \u201edisease\u201c in dermatology. J\u00a0Dtsch Dermatol Ges 13(10):1026\u20131027","journal-title":"J Dtsch Dermatol Ges"},{"key":"5436_CR12","doi-asserted-by":"crossref","unstructured":"Gabutti M, Heidemeyer K, Seyed Jafari SM et\u00a0al (2023) Dimethyl Fumarate Used as an Effective Treatment for Granuloma Annulare Disseminatum: An Immunohistochemical Case Study. Int J Mol Sci 24(17)","DOI":"10.3390\/ijms241713355"},{"key":"5436_CR13","doi-asserted-by":"crossref","unstructured":"de Greef A, Benjelloun G, Harkemanne E et\u00a0al (2024) Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib. Dermatol Ther","DOI":"10.1007\/s13555-024-01117-z"},{"issue":"1","key":"5436_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaad.2021.06.867","volume":"87","author":"ML Hrin","year":"2022","unstructured":"Hrin\u00a0ML, Feldman\u00a0SR, Huang\u00a0WW (2022) Hydroxychloroquine for generalized granuloma annulare: 35\u202f% response rate in a\u00a0retrospective case series of 26\u00a0patients. J\u00a0Am Acad Dermatol 87(1):144\u2013147","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5436_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaad.2021.07.037","volume":"87","author":"ML Hrin","year":"2022","unstructured":"Hrin\u00a0ML, Bowers\u00a0NL, Feldman\u00a0SR et\u00a0al (2022) Methotrexate for generalized granuloma annulare: A\u00a060\u202f% response rate in a\u00a0retrospective case series of 15\u00a0patients. J\u00a0Am Acad Dermatol 87(1):201\u2013203","journal-title":"J Am Acad Dermatol"},{"key":"5436_CR16","doi-asserted-by":"crossref","unstructured":"Jadoul A, Huygen L, Leemans G et\u00a0al (2023) JAK\u00a01\/2 pathway-specific treatment of disseminated granuloma annulare with baricitinib. J\u00a0Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.19073"},{"issue":"1","key":"5436_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40257-021-00636-1","volume":"23","author":"TP Joshi","year":"2022","unstructured":"Joshi\u00a0TP, Duvic\u00a0M (2022) Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol 23(1):37\u201350","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"5436_CR18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1468-3083.2011.04303.x","volume":"26","author":"A Klein","year":"2012","unstructured":"Klein\u00a0A, Coras\u00a0B, Landthaler\u00a0M et\u00a0al (2012) Off-label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a\u00a0retrospective study. J\u00a0Eur Acad Dermatol Venereol 26(11):1400\u20131406","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"5436_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/12034754211048679","volume":"26","author":"M Lam","year":"2022","unstructured":"Lam\u00a0M, Hilal\u00a0MA (2022) Generalized Granuloma Annulare: A\u00a0Retrospective Study From Southern Ontario, Canada. J\u00a0Cutan Med Surg 26(2):208\u2013209","journal-title":"J Cutan Med Surg"},{"key":"5436_CR20","doi-asserted-by":"crossref","unstructured":"Michels A, Heiland R, Hammerschmidt S et\u00a0al (2024) Successful treatment of recalcitrant generalized granuloma annulare with the JAK inhibitor abrocitinib. J\u00a0Dtsch Dermatol Ges","DOI":"10.1111\/ddg.15426"},{"issue":"1","key":"5436_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaad.2019.12.028","volume":"83","author":"MS Min","year":"2020","unstructured":"Min\u00a0MS, Wu\u00a0J, He\u00a0H et\u00a0al (2020) Granuloma annulare skin profile shows activation of T\u2011helper cell type\u00a01, T\u2011helper cell type\u00a02, and Janus kinase pathways. J\u00a0Am Acad Dermatol 83(1):63\u201370","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5436_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1525-1470.1984.tb00437.x","volume":"2","author":"RL Modlin","year":"1984","unstructured":"Modlin\u00a0RL, Horwitz\u00a0DA, Jordan\u00a0RR et\u00a0al (1984) Immunopathologic demonstration of T lymphocyte subpopulations and interleukin\u00a02 in granuloma annulare. Pediatr Dermatol 2(1):26\u201332","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"5436_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000507247","volume":"236","author":"TM Nordmann","year":"2020","unstructured":"Nordmann\u00a0TM, Kim\u00a0J\u2011R, Dummer\u00a0R et\u00a0al (2020) A Monocentric, Retrospective Analysis of 61\u00a0Patients with Generalized Granuloma Annulare. Dermatology 236(4):369\u2013374","journal-title":"Dermatology"},{"key":"5436_CR24","doi-asserted-by":"crossref","unstructured":"Rachamadugu K, Madke B, Talasila SR et\u00a0al (2024) Disseminated granuloma annulare: a\u00a0cutaneous sign of diabetes mellitus. BMJ Case Rep 17(3)","DOI":"10.1136\/bcr-2024-260016"},{"issue":"2","key":"5436_CR25","first-page":"102","volume":"103","author":"CB Rubin","year":"2019","unstructured":"Rubin\u00a0CB, Rosenbach\u00a0M (2019) Granuloma annulare: a\u00a0retrospective series of 133 patients. Cutis 103(2):102\u2013106","journal-title":"Cutis"},{"issue":"6","key":"5436_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1046\/j.1365-2230.1999.00532.x","volume":"24","author":"J Setterfield","year":"1999","unstructured":"Setterfield\u00a0J, Huilgol\u00a0SC, Black\u00a0MM (1999) Generalised granuloma annulare successfully treated with PUVA. Clin Exp Dermatol 24(6):458\u2013460","journal-title":"Clin Exp Dermatol"},{"key":"5436_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdcr.2023.01.027","volume":"34","author":"KN Slater","year":"2023","unstructured":"Slater\u00a0KN, Valk\u00a0B, Kartono\u00a0F (2023) A case of generalized granuloma annulare treated with upadacitinib. JAAD Case Rep 34:12\u201314","journal-title":"JAAD Case Rep"},{"issue":"1","key":"5436_CR28","doi-asserted-by":"publisher","first-page":"e15211","DOI":"10.1111\/dth.15211","volume":"35","author":"W Sondermann","year":"2022","unstructured":"Sondermann\u00a0W, Hadaschik\u00a0E, Specker\u00a0C (2022) Successful therapy of disseminated patch-type granuloma annulare with upadacitinib in a\u00a0patient with rheumatoid arthritis. Dermatol Ther 35(1):e15211","journal-title":"Dermatol Ther"},{"issue":"3","key":"5436_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40257-017-0334-5","volume":"19","author":"J Wang","year":"2018","unstructured":"Wang\u00a0J, Khachemoune\u00a0A (2018) Granuloma Annulare: A\u00a0Focused Review of Therapeutic Options. Am J Clin Dermatol 19(3):333\u2013344","journal-title":"Am J Clin Dermatol"},{"key":"5436_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jdcr.2023.11.024","volume":"44","author":"J Zheng","year":"2024","unstructured":"Zheng\u00a0J, Sharma\u00a0S, Wassell\u00a0K et\u00a0al (2024) Letter to the Editor: Effective treatment of disseminated granuloma annulare with upadacitinib. JAAD Case Rep 44:98\u2013100","journal-title":"JAAD Case Rep"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05436-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:03:17Z","timestamp":1736334197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05436-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["5436"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05436-2","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"3 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Niebel erhielt in den Jahren 2015 bis 2024 finanzielle Unterst\u00fctzung (Forschungsvorhaben, klinische Studien, Beraterhonorare, Referentenhonorare oder Reisekostenerstattung) durch folgende Firmen: AbbVie, Almirall, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Lilly, L\u2019Oreal\/Cerave, MSD, Novartis, Pfizer, Regeneron und UCB Pharma. K. Drexler erhielt in den Jahren 2015 bis 2024 finanzielle Unterst\u00fctzung (Forschungsvorhaben, klinische Studien, Beraterhonorare, Referentenhonorare oder Reisekostenerstattung) durch folgende Firmen: AbbVie, Bristol-Myers Squibb, MSD, Novartis und Pierre Fabre. M.\u00a0Spindler, M.\u00a0Berneburg, B.\u00a0Kurz und J.\u00a0K\u00f6gel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren. Es wurde ein Ethikvotum der Ethikkommission an der Universit\u00e4t Regensburg erteilt (Antrag \u2013 23-3541-104). Open Access-Ver\u00f6ffentlichung erm\u00f6glicht durch DEAL Agreement. Alle Patientinnen und Patienten haben ihr schriftliches Einverst\u00e4ndnis zur Verwendung des Bildmaterials erteilt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}